Novartis Oncology的动态

#NETcancerday2024 Observing #neuroendocrinetumour day last Monday! ??One of the crucial take away points for me, is the emphasis put on the importance of #earlierdiagnosis as it has profound impact on outcomes. ??A large global survey on patient-reported outcomes was undertaken in 2014 and found a mean time to diagnosis of 59?months for US GEP-NET patients, and 52?months for the global population across all entities. For 29% of all patients of the global population, time to diagnosis was longer than 5?years! [1] ??However, prognosis is highly variable and clearly linked to how advanced the disease already is at time of diagnosis: For patients with localized tumours, the mean 5-year survival is 97%, which is much higher than those for regionally and extensively spread tumours, which are 81% and 39%, respectively. [2] ?This means we need to double down on the effort developing highly predictive models, that can help doctors identify people that have NETs much earlier! ??For better outcomes for patients. We know this can be done. Intrigued? Then get in touch! #inTrigue #inFlow #GEPNET #aiinnovationinhealth #diagnosticsupporttools with Volv Global SA, ?? Christopher Rudolf 1] https://lnkd.in/eknqU7sn [2] https://lnkd.in/ev9E5ErM https://lnkd.in/efAqZkqN

Did you know? Liver cancer is one of the most common cancers globally. This #WorldLiverDay, I encourage all you working professionals to learn about the symptoms of liver disease and take this as an opportunity to get your checkup done. Early diagnosis can significantly improve treatment outcomes. Share this post to spread awareness! #LiverCancer #EarlyDetectionSavesLives #Oncology #Oncologist #LiverDay #LoveYourLiver

Happy to share our recently published study in the PNAS Journal that sheds new light on the fascinating mechanisms behind Porphyromonas gingivalis and its ability to evade the immune system in periodontitis! ???? This research identifies CD47 as a key player in the survival strategy of this oral pathogen, demonstrating how it interacts with TLR2 to suppress immune defenses. Moreover, we explored the role of thrombospondin-1 (TSP-1) in broad suppression of neutrophil activity, revealing potential pathways to target for controlling P. gingivalis-related diseases, including cardiovascular disease, Alzheimer's, and cancer. This study highlights an innovative approach to tackling pathogen-induced chronic inflammation and systemic health risks, which are deeply connected to oral health. You can check out the paper here: https://lnkd.in/d8ZGNK7u

For decades, the hypothesis of tau as a therapeutic target for curing Alzheimer's disease (AD) has faced skepticism. Critics often point to the numerous failed anti-tau clinical trials as evidence that targeting tau is unviable. Despite this, efforts to address tau pathology in AD continue unabated, driven by its well-documented role in disease progression. Recently, the tau antibody Bepranemab failed to meet its primary clinical endpoint, further fueling doubt. However, this trial also yielded promising results, demonstrating a 63%–67% reduction in pathological tau accumulation and a 29% slower rate of cognitive decline in low-tau and non-APOE4 AD patients. Crucially, it established a tangible link between tau pathology and cognitive benefit in this subset of patients. https://lnkd.in/gHp-FMNR #Alzheimer's disease

?? Highlights from Dr. Marianna Spatola, MD PhD insightful presentation on Autoimmune Encephalitis and its Pathogenic Mechanisms. Dr. Spatola discussed different forms of antibody-mediated #encephalitis, particularly NMDA-R and LGI1 encephalitis, emphasizing a key takeaway: the importance of?recognizing?#cognitive #impairment?related to?encephalitis.??? Key points: ? The critical role of #antibodies in autoimmune encephalitis. ? The positive impact of timely #immunotherapy. ? The importance of research for better-targeted therapeutic strategies. And after exploring diseases that can be treated with immunotherapy, today at 11.00 ?? we will shift to #neurodegenerative diseases and the #Tau Hypothesis with Dr. Clément DANIS’ presentation on?“Tau tau tau: l’expérience lilloise”. ?? A big thank you to Dr. Spatola for this enriching presentation, and looking forward to Dr. Danis' insights! ??

Expert Insights: Role of Nutrition in Recovering Cachexia! Listen to Dr. Nadeem Ahmed - Medial and Hemat Oncologist, Hyderabad regarding valuable insights on cancer cachexia, a condition that often affects patients undergoing cancer treatment. Dr. Nadeem emphasizes the crucial role of nutrition in managing cachexia that enhances well-being during treatment. Join Us in the Campaign for Freedom from Cancer Cachexia! Visit our website: ?? www.betadrugslimited.com #AdleyOncology #freedomfromcancercachexia #DrNadeemAhmed #CancerCachexia #ExpertInsights #HealthcareInsights #CancerAwareness #MedicalInsights #HealthandWellness #NutritionTherapy #MedicalScience #PatientWellbeing

As rigorous studies with multiple research partners continue, we are excited to see novel findings being discovered with the use of our #AI technology, potentially enabling groundbreaking innovations in the treatment of complex vascular diseases like pulmonary hypertension (PH). Prof. Julien Guiot shared his thoughts on the current state of AI and our software: "I believe that AI has an incredible potential to enable major improvements in treatment of PH, specifically when it comes to identification of patients with P(A)H. Having an invasive hemodynamic catheterization as the gold standard, we are also evaluating the correlation between vascular biomarkers and hemodynamics. If we can confirm that the combination of symptoms, echocardiography (ECG) and CT could aid us in a more accurate diagnosis of patients at risk of pulmonary (arterial) hypertension, we could transform the way it is diagnosed today and show that it could be less invasive and could help as a clinical decision support tool." Read more on new ways to phenotype vascular lung disease patients with imaging-based markers: https://lnkd.in/eMkhsuzJ

July is?Sarcoma Awareness Month. Sarcoma is a group of cancers that begin in the bones and soft tissues. Tenosynovial giant cell tumor (TGCT) is a non-malignant, debilitating disease that also invades soft tissues and causes joint damage, swelling, pain, and reduced function. By sharing knowledge, resources and best practices we can make a difference for patients. Increased collaboration among medical professionals, researchers, patient advocacy groups and other stakeholders leads to better and earlier diagnoses, improved therapies, and better outcomes for those battling this rare disease. At SynOx we are dedicated to supporting this vision.? ? #SarcomaAwareness #RareDisease #TGCT ?

?? New research by Harvard University highlights the potential of #extracellularvesicles (EVs) as biomarkers for #Parkinson's disease diagnosis. EVs could improve early detection and patient monitoring, offering a promising path for precision medicine. Read here: https://lnkd.in/e2WN4Mtv World CNS Series #CNS #Alzheimers #Parkinsons #ALS